Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy. The poor response of cancer cells to immune destruction is an essential contributor to the failure of checkpoint therapy. We hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Qingqing, Li, Xiaotong, Liu, Chang, Jiang, Yuxin, He, Yonglong, Zhang, Wanting, Azevedo, Helena S., Wu, Wei, Xia, Yuanzheng, He, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465872/
https://www.ncbi.nlm.nih.gov/pubmed/37655330
http://dx.doi.org/10.1016/j.apsb.2022.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465872/
https://www.ncbi.nlm.nih.gov/pubmed/37655330
http://dx.doi.org/10.1016/j.apsb.2022.07.012

Ejemplares similares